Tivic Health Systemsは2025年第3四半期に12%の収益増加を記録したが,全年収益見通しを維持しながら,より高いR&D支出によるより大きな純損失を報告した. Tivic Health Systems saw 12% revenue growth in Q3 2025 but reported a larger net loss due to higher R&D spending, while maintaining full-year revenue outlook.

Tivic Health Systemsは2025年第3四半期財務結果を報告し,診断画像製品の売上高の増加により,昨年同期比12%増加した1,4200万ドルの収益を明らかにした. Tivic Health Systems reported third quarter 2025 financial results, disclosing revenue of $142 million, a 12% increase from the same period last year, driven by higher sales of its diagnostic imaging products. 同社は,前期四半期における1億400万ドルの損失と比較して,研究費の増加と開発費の増額を訴えた. The company posted a net loss of $18 million, compared to a $14 million loss in the prior-year quarter, citing increased research and development expenses. Tiviは2025年度の全収入ガイドラインを維持し,総収入は5億6000万ドルから5億5億5千万円と予想している. Tivic maintained its full-year 2025 revenue guidance, expecting total revenue between $560 million and $575 million.